3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Head and Neck Neoplasms
3
Melanoma
2
Lung Neoplasms
2
Carcinoma, Squamous Cell
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Tumor, Adult
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Cyclophosphamide
3
fludarabine
2
Radiotherapy
2
Interleukin-2
2
tislelizumab
1
pembrolizumab
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
niraparib
1
neotil
1
lenvatinib
1
atezolizumab
1
Yoga
1
X-Rays
1
Watchful Waiting
1
Tomography, X-Ray Computed
1
Tiragolumab
1
Surveys and Questionnaires
1
Radiation
1
Positron-Emission Tomography
1
Nivolumab
1
Magnetic Resonance Imaging
1
Lacteol
1
Ipilimumab
1
High-Throughput Nucleotide Sequencing
1
Fluorodeoxyglucose F18
1
Data Collection
1
Cryosurgery
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumor, Adult
×
Tiragolumab
×
Clear all
NCT06003621
2024-11-15
MoST-TAP
Omico
Phase 2
Recruiting
96 enrolled